Over the past 12 months, 4 insiders at Xenon Pharmaceuticals Inc. filed 23 open-market SEC Form 4 transactions on XENE: 0 purchases worth $0 and 23 sales worth $21.8M. Insiders have been net sellers over this period. The most recent filing was on Jun 5, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 5, 26 | Gillian Cannon | SELL | 1.2K | $53.14 | $63K |
| Mar 13, 26 | Andrea DifabioChief Legal Officer | SELL | 1.3K | $55.23 | $74K |
| Mar 13, 26 | Christopher John KenneyChief Medical Officer | SELL | 1.4K | $55.23 | $78K |
| Mar 13, 26 | Ian MortimerPRESIDENT & CEO | SELL | 7.3K | $55.23 | $404K |
| Mar 10, 26 | Andrea DifabioChief Legal Officer | SELL | 2.6K | $60.11 | $157K |
| Mar 10, 26 | Christopher John KenneyChief Medical Officer | SELL | 2.8K | $60.11 | $167K |
| Mar 10, 26 | Ian MortimerPRESIDENT & CEO | SELL | 11.3K | $60.11 | $677K |
| Mar 9, 26 | Ian MortimerPRESIDENT & CEO | SELL | 65.0K | $62.06 | $4.0M |
| Jan 2, 26 | Ian MortimerPRESIDENT & CEO | SELL | 37.9K | $44.93 | $1.7M |
| Dec 8, 25 | Ian MortimerPRESIDENT & CEO | SELL | 8.8K | $46.32 | $402K |
| Dec 5, 25 | Ian MortimerPRESIDENT & CEO | SELL | 14.4K | $45.03 | $647K |
| Nov 28, 25 | Ian MortimerPRESIDENT & CEO | SELL | 97 | $45.01 | $4K |
| Oct 1, 25 | Ian MortimerPRESIDENT, CEO & INTERIM CFO | SELL | 25.0K | $40.16 | $1.0M |
| Jun 5, 25 | Steven GannonDirector | SELL | 3 | $30.48 | $91 |
| Jan 27, 25 | Ian MortimerPRESIDENT & CEO | SELL | 15.2K | $41.07 | $614K |
| Jan 24, 25 | Ian MortimerPRESIDENT & CEO | SELL | 22.5K | $40.20 | $903K |
| Jan 23, 25 | Ian MortimerPRESIDENT & CEO | SELL | 16.2K | $40.08 | $650K |
| Dec 18, 24 | Sherry AulinChief Financial Officer | SELL | 11.5K | $41.23 | $474K |
| Nov 22, 24 | Gary PatouDirector | SELL | 2.9K | $41.11 | $117K |
| Mar 8, 24 | Elizabeth A. GarofaloDirector | SELL | 2.1K | $45.69 | $96K |
| Mar 7, 24 | Steven GannonDirector | SELL | 5.0K | $46.45 | $232K |
| Mar 7, 24 | Sherrington RobinEVP, Strategy & Innovation | SELL | 6.1K | $46.30 | $283K |
| Dec 14, 23 | Gary PatouDirector | SELL | 7.6K | $41.05 | $312K |
| Dec 13, 23 | Gary PatouDirector | SELL | 7.6K | $41.05 | $312K |
| Aug 24, 23 | Dawn SvoronosDirector | SELL | 25.0K | $38.70 | $968K |
| Jun 1, 23 | Simon N. PimstoneDirector | SELL | 24.3K | $38.97 | $941K |
| May 31, 23 | Simon N. PimstoneDirector | SELL | 26.9K | $38.81 | $1.0M |
| May 30, 23 | Simon N. PimstoneDirector | SELL | 19.0K | $39.90 | $758K |
| May 24, 23 | Ian MortimerPRESIDENT & CEO | SELL | 17.1K | $41.49 | $707K |
| Mar 24, 23 | Christopher John KenneyChief Medical Officer | SELL | 700 | $35.01 | $25K |
| Mar 7, 23 | Simon N. PimstoneDirector | SELL | 11.0K | $37.01 | $407K |
| Nov 25, 22 | Gary PatouDirector | SELL | 1.9K | $34.79 | $67K |
| Nov 23, 22 | Gary PatouDirector | SELL | 2.1K | $34.33 | $71K |
| Sep 2, 22 | Sherry AulinChief Financial Officer | SELL | 15.4K | $39.57 | $608K |
| Sep 1, 22 | Sherrington RobinEVP, Strategy & Innovation | SELL | 35.1K | $38.80 | $1.3M |
| Aug 31, 22 | Sherrington RobinEVP, Strategy & Innovation | SELL | 21.4K | $38.57 | $824K |
| Aug 16, 22 | Simon N. PimstoneDirector | SELL | 32.1K | $38.87 | $1.2M |
| Aug 15, 22 | Simon N. PimstoneDirector | SELL | 33.9K | $37.76 | $1.3M |
| Aug 12, 22 | James R. EmpfieldEVP, Drug Discovery | SELL | 35.9K | $38.68 | $1.4M |
| Aug 12, 22 | Simon N. PimstoneDirector | SELL | 47.0K | $39.15 | $1.8M |
| Mar 8, 22 | Simon N. PimstoneDirector | SELL | 2.5K | $30.80 | $77K |
| Mar 7, 22 | James R. EmpfieldEVP, Drug Discovery | SELL | 31.0K | $30.62 | $948K |
| Mar 7, 22 | Simon N. PimstoneDirector | SELL | 7.5K | $30.60 | $229K |
| Mar 4, 22 | James R. EmpfieldEVP, Drug Discovery | SELL | 18.3K | $30.79 | $564K |
| Mar 4, 22 | Simon N. PimstoneDirector | SELL | 4.8K | $30.66 | $146K |
| Mar 4, 22 | Sherrington RobinEVP, Strategy & Innovation | SELL | 6.7K | $30.56 | $205K |
| Jan 21, 22 | Christopher John KenneyChief Medical Officer | BUY | 700 | $28.81 | $20K |
| Dec 6, 21 | Seggern Christopher VonChief Commercial Officer | BUY | 4.0K | $24.40 | $98K |
| Nov 15, 21 | Simon N. PimstoneDirector | SELL | 17.6K | $31.33 | $550K |
Over the past 12 months, insiders at Xenon Pharmaceuticals Inc. filed 0 open-market purchases worth $0 and 23 sales worth $21.8M on XENE, which makes them net sellers over the period. The most recent Form 4 was filed on Jun 5, 26.
The largest recent open-market XENE insider purchase in our data was $98K by Seggern Christopher Von, Chief Commercial Officer, filed on Dec 6, 21.
4 different insiders at Xenon Pharmaceuticals Inc. filed open-market SEC Form 4 transactions on XENE over the last 12 months.
InsiderTape plots every XENE insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Xenon Pharmaceuticals Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →